INS1203 — IND submission
in 2026
Insmed's third gene therapy candidate, INS1203, targeting Stargardt disease, is currently advancing toward the clinic, with an IND filing expected in 2026.Source filing
INSM biotech catalysts & pipeline
INSMED INC · Data as of 2026-09-08
Upcoming catalysts
ARIKAYCE (amikacin liposome inhalation suspension) — FDA meeting
H2 2026
We also plan to review the data with the Pharmaceuticals and Medical Devices Agency (PMDA) in the second half of 2026 to support potential label expansion in Japan.Source filing
BRINSUPRI (brensocatib) — Regulatory decision
H2 2026
We continue to anticipate a regulatory decision for brensocatib for the treatment of NCFB in Japan in the second half of 2026.Source filing
INS1033 — IND submission
H2 2026
Insmed's second dipeptidyl peptidase 1 (DPP1) inhibitor, INS1033, is currently advancing toward the clinic in rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), with an initial investigational new drug (IND) filing expected in the second half of 2026.Source filing